Compare iShares iBoxx $ High Yield Corporate Bond ETF (HYG) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ High Yield Corporate Bond ETF vs IDEXX Laboratories, Inc. — how do they compare? iShares iBoxx $ High Yield Corporate Bond ETF trades at $77.22 (market cap $17.89B), while IDEXX Laboratories, Inc. trades at $516.73 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 2.3× iShares iBoxx $ High Yield Corporate Bond ETF's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 44,866,592). Which is the better fit depends on your goals — on Pluang, investors hold iShares iBoxx $ High Yield Corporate Bond ETF for 60 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| HYG | IDXX | |
|---|---|---|
Market Cap | $17.89B | $40.43B |
Volume | 44,866,592 | 692,164 |
Sector | Fixed Income | Health |
52-Week High | $81.28 | $766.68 |
52-Week Low | $76.90 | $504.70 |
Typical Hold Time | 60 Days | 46 Days |
Enterprise Value | — | $41.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HYG trades at $77.205, showing minimal daily movement with a 0.03% gain. Technical indicators signal a bearish trend with moving averages and ADX pointing downward, though RSI suggests potential oversold conditions. The ETF maintains regular dividend distributions, with recent payouts ranging from $0.38 to $0.44. Market focus remains on high-yield bond performance amid rising Treasury yields and Federal Reserve policy uncertainty.
The outlook for HYG remains challenged by persistent bond market volatility and rising interest rates. While the fund's consistent dividend payments provide income support, the bearish technical setup and macroeconomic headwinds suggest continued pressure on high-yield corporate bonds. Investors face risks from credit quality deterioration and duration exposure in a rising rate environment.
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
